Jun 21, 2014 · Here, we report that treating human HNSCC cells in vitro with a human anti-ADAM17 inhibitory antibody, D1 (A12), suppresses proliferation and motility in the absence or presence of the EGFR tyrosine kinase inhibitor (TKI) gefitinib.

Here, we report that treating human HNSCC cells in vitro with a human anti-ADAM17 inhibitory antibody, D1 (A12), suppresses proliferation and motility in the absence or presence of the EGFR tyrosine kinase inhibitor (TKI) gefitinib.

Huang Y., Benaich N., Tape C., Kwok H. F., Murphy G. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.

Nov 9, 2021 · Huang Y., Benaich N., Tape C., Kwok H.F., Murphy G. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1 (A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.

This approach allowed the isolation of an ADAM17 cross-domain inhibitory antibody, called D1(A12), which is a fivefold better inhibitor than TIMP-3 in blocking ADAM17-dependent shedding of TNF and EGF-like ligands.

D1(A12) IgG showed a significant reduction in tumour growth (p = 0.005), 56% of vehicle control. Surprisingly, D1(A12) did not reduce the concentration of circulating human TNF-α, suggesting that another enzyme may compensate for inhibition of ADAM17 in vivo (but not in vitro).

May 5, 2021 · In a cell-based assay using Adam10/17 double-knockout mouse embryonic fibroblasts (Adam10 / 17−/− mEFs) exogenously expressing each of these mutants, phorbol 12-myristate 13-acetate-stimulated...

Jun 9, 2015 · Results: D1(A12) was found to significantly inhibit the release of TGFα, and to decrease downstream EGFR-dependent cell signalling. D1(A12) treatment reduced proliferation in two-dimensional clonogenic assays, as well as growth in three-dimensional culture.

Recent studies reported that anti-ADAM17 D1(A12) monoclonal antibody, the first specific inhibitor for ADAM17, showed anti-tumor effect in vitro and in vivo (15,16). This monoclonal antibody simultaneously binds to catalytic and disintegrin domains.

Jun 21, 2014 · Here, we report that treating human HNSCC cells in vitro with a human anti-ADAM17 inhibitory antibody, D1 (A12), suppresses proliferation and motility in the absence or presence of the EGFR tyrosine kinase inhibitor (TKI) gefitinib.